Floatz logo

VINCRISTINE SULFATE

Myelodysplastic Syndrome (MDS)

Prelude TherapeuticsSmall moleculePhase 1Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Myelodysplastic Syndrome (MDS) cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Muromonab-Cd3
St. Jude Children's Research Hospital
Phase 3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB
Zanubrutinib
Medical College of Wisconsin
Phase 2B
pr1:169-177 peptide
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B

View all 38 →

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →